论文部分内容阅读
目的探讨不同剂量阿扎司琼对子宫肌瘤腹腔镜下子宫次全切除术后恶心呕吐的疗效。方法选取2013年3月至2014年3月间收治的60例子宫肌瘤腹腔镜下子宫次全切除术患者为研究对象,采用随机数字表法分为A组、B组和C组,每组20例。于手术结束前20 min分别给予A组、B组和C组患者阿扎司琼5 mg、阿扎司琼10 mg和生理盐水静脉注射。观察术后24 h内3组患者恶心、呕吐的发生率及严重程度,并对术后并发症进行比较。结果 A组与B组患者术后24 h内恶心、呕吐的发生率比较,差异无统计学意义(P>0.05)。与C组患者比较,A组患者和B组患者术后24 h内恶心、呕吐的发生率均较低,差异有统计学意义(P<0.05)。A组患者不良反应的发生率明显低于B组患者,组间差异有显著统计学意义(P<0.01)。结论阿扎司琼5 mg可有效减少子宫肌瘤腹腔镜下子宫次全切除术后恶心呕吐的发生率,且具有较好的安全性,值得临床推广应用。
Objective To investigate the curative effect of different doses of azaseon on hysteric vomiting after laparoscopic hysterectomy of uterine fibroids. Methods Sixty patients with hysteromyoma underwent laparoscopic hysterectomy between March 2013 and March 2014 were enrolled in this study. Patients were divided into groups A, B and C by random number table, and each group 20 cases. Patients in group A, group B and group C were treated with 5 mg of atazionine and 10 mg of atazan and intravenous injection of saline respectively 20 minutes before the end of surgery. The incidence and severity of nausea and vomiting in the three groups were observed within 24 hours after operation. Complications were compared between the two groups. Results There was no significant difference in the incidence of nausea and vomiting between groups A and B within 24 hours after operation (P> 0.05). Compared with group C, the incidence of nausea and vomiting was lower in group A and group B within 24 hours after operation, the difference was statistically significant (P <0.05). The incidence of adverse reactions in patients in group A was significantly lower than that in patients in group B, with significant differences between groups (P <0.01). Conclusion Azathimmun 5 mg can effectively reduce the incidence of nausea and vomiting after hysterectomy and hysterectomy of uterine fibroids, and has good safety and worthy of clinical application.